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1) Unit for Infectious Diseases, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm and 2) Section of Infectious Diseases,
Department of Medical Sciences, Uppsala University, Uppsala, SwedenAbstractAcute bacterial meningitis (ABM) is challenging for the admitting physician because it is a rare but fulminant disease, usually presenting without
typical symptoms, and rapid treatment is pivotal. The purpose of this study was to evaluate the effect of initial management by infectious
diseases (ID) physicians vs. non-ID physicians. A total of 520 consecutive adults (>17 years old), 110 with initial ID management and 410
with non-ID management, registered in the Swedish quality registry for community-acquired ABM January 2008 to December 2013, were
analysed retrospectively. Primary outcome was appropriate treatment with antibiotics and corticosteroids <1 hour from admission.
Secondary analyses were mortality during hospital stay and persisting neurological and hearing deﬁcits at follow-up after 2 to 6 months.
Differences in diagnostic treatment sequences also were analysed. Appropriate treatment <1 hour from admission was achieved
signiﬁcantly more often (41%) by ID physicians vs. non-ID physicians (24%) with an odds ratio (OR) of 2.4 (95% conﬁdence interval [CI]:
1.40 to 4.14; p < 0.01) adjusted for confounders. The door-to-antibiotic time was signiﬁcantly shorter, and signiﬁcantly more patients
were administered corticosteroids together with the ﬁrst doses of antibiotics in the ID group. A trend of decreased mortality (4.5% vs.
8.0%) and sequelae at follow-up (24% vs. 44%; adjusted OR 0.55: 95% CI 0.31 to 1.00; p 0.05) were observed in the ID group vs. the
non-ID group. Antibiotics were started without prior neuroimaging more often in the ID group (86% vs. 57%; p < 0.001). Initial
management at the emergency department by ID physicians is associated with earlier appropriate treatment, more appropriate diagnostic
treatment sequences and favourable outcome.
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E-mail: martin.glimaker@karolinska.seIntroductionAcute bacterial meningitis (ABM) is a rare but potentially life-
threatening disease, especially if of nonmeningococcal aeti-
ology, with a mortality of 5% to 30% and a high risk of
neurological deﬁcits despite modern treatment and advanced
intensive care [1–5]. Impaired mental status, older age,Microbiol Infect 2015; 21: 560–566
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.02.023comorbidity, nonmeningococcal aetiology and fulminant disease
are reported risk factors for poor outcome [5–8]. Recent
studies also have indicated that delayed antibiotic treatment
constitutes a major risk factor for poor outcome [1–3,7–11]
and a large randomized clinical trial has demonstrated signiﬁ-
cantly lower mortality if corticosteroid treatment was added
[12]. Thus, early appropriate treatment with antibiotics and
corticosteroids in meningitis doses are pivotal in ABM, and
current recommendations state that this should be adminis-
tered within 1 hour from admission [7,8,13–16]. However,
median time from admission to start of treatment is reported
to be 2 to 4 hours [1–3,10,11]. This doctor’s delay has been
associated with difﬁculties in recognising ABM due to absenceious Diseases. Published by Elsevier Ltd. All rights reserved
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diagnostic treatment sequences [1,3,7,8,10,17]. The sequence
of computed tomography (CT) of the brain followed by lumbar
puncture (LP) followed by treatment is common and has been
identiﬁed as a risk factor for mortality [3,7,8].
In Sweden, infectious diseases (ID) constitute a separate
speciality, requiring 5 years of postgraduate training and ex-
aminations. Adults with ABM are usually treated at ID clinics,
but the initial management is often performed by physicians of
other specialities. Earlier studies have indicated that ID spe-
cialists are valuable in the management of blood stream in-
fections, endocarditis, pneumonia, and urinary tract infections
[18–23]. However, the value of an ID physician in the pri-
mary management of admission of adults with ABM is unknown.
The objective of the present study was to investigate differ-
ences in initial management of patients with ABM by ID phy-
sicians (ID group) vs. non-ID physicians (non-ID group). The
primary outcome was administration of appropriate antibiotics
and corticosteroids within 1 hour from admission. Secondary
outcome was time from admission to start of antibiotic treat-
ment. Additionally, differences in diagnostic treatment se-
quences were analysed. Finally, we assessed the effect of
medical speciality on mortality during hospital stay and sequelae
at follow-up after 2 to 6 months.Material and methodsPatients
All adult patients (>17 years old) with community-acquired
ABM, treated at all 27 Swedish ID clinics located at larger
Provincial or University hospitals, are eligible for inclusion in
the Swedish quality registry of bacterial meningitis (SQRM). On
admission, patients with suspected ABM are triaged to an ID or
a non-ID physician mainly based on local traditions. ID physi-
cians are present at the emergency room around the clock at
four of the eight University hospitals, but only from 8 AM to
around 10 PM in the other hospitals. The ABM diagnoses are
deﬁned by specialists in ID, and based on clinical conventional
diagnostic criteria with or without cerebrospinal ﬂuid (CSF)
analyses. Patients with meningococcal disease without menin-
gitis were not included. The study comprised ABM patients
registered in SQRM during the period January 2008 to
December 2013. Episodes were deﬁned as community-
acquired if the patient had not been hospitalized within 30
days before admission. During the 6-year period, 623 adults
with community-acquired ABM were registered, representing
about 85% of all adult cases with ABM in Sweden according to
data from the National Board of Health and Welfare in Sweden
(personal communication). Data on the primary managingClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyphysician were available in 520 (83.5%) cases. Of these, initial
management at the emergency departments was performed by
ID physicians in 110 (21.2%; ID group). The remaining 410
cases (non-ID group) were initially managed by internal medi-
cine physicians (n = 213), emergency physicians (n = 150),
neurologists (n = 10) or other physicians (n = 37). The pro-
portions of patients with initial ID management were similar in
university (21.8%) as in other hospitals (19.9%).
LP was performed in 479 cases, and positive culture and/or
polymerase chain reaction and/or microscopy and/or antigen
detection in CSF were obtained in 390 (75.0%) of the 520
patients. Positive blood cultures were detected in 333 (64.0%)
patients. In 48 patients (9.2%) the cultures were negative and
the aetiological diagnosis was unknown. In 40 of these 48 pa-
tients, CSF ﬁndings (leukocyte count, glucose, protein or lactate
levels) supported the ABM diagnosis. In the remaining eight
patients, the diagnosis was based on clinical ﬁndings alone.
Study variables
From the registry, sex, age, clinical ﬁndings, aetiology, corti-
costeroid and antibiotic treatment, mortality and sequelae were
obtained (Table 1). Mental status was assessed by the initial
managing physician as soon as possible on admission at the
emergency department and recorded as the reaction level scale
[24,25] and/or the Glasgow coma scale. The time point for
admission was deﬁned as the time for triage at admission, and
the door-to-antibiotic time was registered as deﬁnite intervals:
0 to 0.5, 0.5 to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 6, 6 to 8, 8 to 12 or
>12 hours.
Corticosteroid treatment concomitant with the start of anti-
biotics was deﬁned as administration of dexamethasone or beta-
methasone in ABM doses within 1 hour from the start of
antibiotics. Appropriate antibiotic treatment was deﬁned as
intravenous β-lactam antibiotics administered in doses for men-
ingitis, for which the isolated bacteria were sensitive. In patients
with unknown aetiology, third-generation cephalosporin ± ampi-
cillin or meropenem was deﬁned as appropriate.
Mortality was recorded during hospital stay, and neurological
and hearing deﬁcits were evaluated at follow-up 2 to 6 months
after discharge. Neurological sequelae were speciﬁed as head-
ache, cognitive dysfunction/dementia, vertigo or fatigue causing
limitations of daily activity, epileptic seizures, ataxia or persistent
neurological deﬁcits. Hearing disability was deﬁned as new onset
of impairment, and audiometry was performed at the discretion
of the physician. The diagnostic sequence of cerebral CT scan in
relation to LP and start of antibiotic treatment was registered.
Statistics
Two-tailed χ2 test was used for categorical data. Mann-Whitney
test was conducted to compare continuous variables. Logisticand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 560–566
TABLE 1. Patient characteristics in relation to study outcomes and medical speciality of initial managing physician
Antibiotics and
corticosteroids <1 h,
n/n available data (%)
Mortality, n/n
available data (%)
Sequelae, n/n
available data (%)
ID physician,
n [ 110 (%)
Non-ID physician,
n [ 410 (%)
p Value, ID vs.
non-ID group
Female (n = 258) 61/225 (27.1) 19/258 (7.4) 83/192 (43.2) 47 (42.7) 211 (51.5) 0.10
Male (n = 262) 64/227 (28.2) 19/262 (7.3) 67/187 (35.8) 63 (57.3) 199 (48.5)
p, Above difference 0.80 0.96 0.14
Age
17-39 y (n = 86) 31/75 (41.3) 0 11/65 (16.9) 27 (24.5) 59 (14.4) 0.07
40-49 y (n = 59) 14/49 (28.6) 2/59 (3.4) 19/46 (41.3) 10 (9.1) 49 (12.0)
50-59 y (n = 85) 23/71 (32.4) 4/85 (4.7) 24/68 (35.3) 21 (19.1) 64 (15.6)
60-69 y (n = 161) 39/144 (27.1) 7/161 (4.3) 61/125 (48.8) 27 (24.5) 134 (32.7)
70 y (n = 129) 18/113 (15.9) 25/129 (19.4) 35/75 (46.7) 25 (22.7) 104 (25.4)
p, Above differences 0.004 <0.001 <0.001
Underlying condition* (n = 188) 32/154 (20.8) 19/188 (10.1) 57/135 (42.2) 39 (35.5) 149 (36.3) 0.86
No underlying condition (n = 332) 93/298 (31.2) 19/332 (5.0) 93/244 (38.1) 71 (64.5) 261 (63.7)
p, Above differences 0.02 0.07 0.43
Symptoms n = 110 n = 408
Typical symptoms† (n = 173) 60/154 (39.0) 4/173 (2.3) 41/133 (30.8) 42 (38.2) 131 (32.1) 0.23
No typical symptoms (n = 345) 65/297 (21.9) 33/345 (9.6) 109/246 (44.3) 68 (61.8) 277 (67.9)
p, Above differences <0.001 0.003 0.01
Respiratory tract infection (n = 242) 67/215 (31.2) 16/242 (6.6) 83/184 (45.1) 55 (50.0) 187 (45.6) 0.41
No respiratory tract infection (n = 278) 58/237 (24.5) 22/278 (7.9) 67/195 (34.4) 55 (50.0) 223 (54.4)
p, Above differences 0.11 0.57 0.03
Mental status on admission n = 107 n = 396
RLS 1 (n = 207) 38/183 (20.8) 5/207 (2.4) 47/160 (29.4) 54 (50.5) 153 (38.6) 0.05
RLS 2 (n = 135) 28/122 (23.0) 8/135 (5.9) 48/105 (45.7) 26 (24.3) 109 (27.5)
RLS 3-4 (n = 128) 45/107 (42.1) 13/128 (10.2) 43/89 (48.3) 25 (23.4) 103 (26.0)
RLS 5-8 (n = 33) 12/26 (46.2) 8/33 (24.2) 11/19 (57.9) 2 (1.9) 31 (7.8)
p, Above differences <0.001 <0.001 0.003
Aetiology
S. pneumoniae (n = 262) 61/230 (26.5) 23/262 (8.8) 88/195 (45.1) 52 (47.3) 210 (51.2) 0.49
N. meningitidis (n = 70) 25/61 (41.0) 2/70 (2.9) 13/51 (25.5) 18 (16.4) 52 (12.7)
Other bacteria (n = 140) 33/120 (27.5) 12/140 (8.6) 42/100 (42.0) 27 (24.5) 113 (27.6)
Unknown‡ (n = 48) 6/41 (14.6) 1/48 (2.1) 7/33 (21.2) 13 (11.8) 35 (8.5)
p, Above differences 0.03 0.16 0.009
ID, infectious disease; RLS, reaction level scale; two-tailed χ2 test was used for p values.
*Malignancy, immunosuppressive treatment including cortisone, HIV infection, diabetes mellitus, alcoholism, intravenous drug abuse, cerebrospinal ﬂuid leakage/previous skull base
fracture or severe liver/kidney failure.
†Fever, headache, neck stiffness on admission.
‡Culture-negative diagnoses; in 40 of these 48 patients cerebrospinal ﬂuid ﬁndings (leukocyte count or glucose, lactate or protein levels) supported the diagnosis. In the remaining 8
patients, the diagnosis was based on clinical ﬁndings alone.
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viously reported important confounders [3,5,6,9,10]: sex, age,
immunocompromised state, clinical presentation with typical
ABM symptoms, mental status on admission, concomitant
respiratory tract infection and aetiology.
Ethics
The study was approved by the ethics committee at Karolinska
Institutet (Dnr 04-1085/1).ResultsPatient characteristics
Characterization of the patient material and possible con-
founders related to the outcomes and study groups are shown
in Table 1. Of the 520 patients, 258 (49.6%) were female and
262 (50.4%) were male. The median age was 61 years, and
underlying conditions were reported in 188 of 520 (36.2%)
cases. Patients in the non-ID group tended to be older (p 0.07)
and more mentally affected (p 0.05) compared with the ID
group. No signiﬁcant difference was observed in patientsClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectwithout, as in those with, information regarding initial managing
physician (data not shown).
Time to treatment
Appropriate antibiotic treatment was initiated <1 hour from
admission in 141 (33.7%) of the 419 patients with available data.
Signiﬁcantly earlier treatment (p < 0.001) and more patients
with a door-to-antibiotic time <1 hour and <2 hours, respec-
tively, were observed in the ID group vs. the non-ID group
(Figs. 1 and 2; Table 2). The adjusted odds ratios (OR) for door-
to-antibiotic time <1 hour and <2 hours, compared with the ID
group with the non-ID group, were 2.25 (95% conﬁdence in-
terval [CI]: 1.31 to 3.85; p 0.003) and 3.74 (95% CI: 2.07 to
6.74; p < 0.001), respectively. Corticosteroids were adminis-
tered concomitant with antibiotics in 83 of 101 (82.2%) patients
with available data in the ID group vs. 262 of 389 (67.4%;
p < 0.01) in the non-ID group.
Data for the primary end point, door-to-antibiotic time <1
hour and concomitant corticosteroid treatment, were available
in 452 of 520 (86.9%) patients; 101 of 110 (91.8%) in the ID
group and 351 of 410 (85.6%) in the non-ID group. An
increased chance to receive appropriate treatment <1 hourious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 560–566
FIG. 1. Proportions of cases started on appropriate antibiotics at
different time intervals from admission, related to whether the patient
was initially managed by an infectious diseases (ID) physician or a non-
ID physician. Signiﬁcantly earlier treatment was observed in the ID
group; p < 0.001 with Mann-Whitney test.
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nonimmunocompromised state, typical symptoms, severely
impaired mental status and meningococcal aetiology (Table 1).
Forty-one of the 101 (40.6%; 95% CI: 30.9 to 50.8) patients in
the ID group received appropriate treatment with antibiotics
and corticosteroids <1 hour from admission vs. 84 (23.9%; 95%
CI: 19.6 to 28.7) of the 351 in the non-ID group (Table 2,
Fig. 2). This difference remained after adjustment for sex, age,
underlying condition, typical ABM symptoms, mental status,
concomitant respiratory tract infection and aetiology (adjusted
OR: 2.41; 95% CI: 1.40-4.14; p 0.001).FIG. 2. Proportions of patients with
door-to-antibiotic time <1 and <2
hours, corticosteroid treatment
concomitant with the ﬁrst dose of
antibiotics (all cases), and start of
appropriate treatment with antibi-
otics and corticosteroids <1 hour,
initially treated by infectious diseases
physicians and noninfectious diseases
physicians, respectively. Two-tailed
χ2 test was performed for p values.
Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyMortality and sequelae
The overall mortality during hospital stay was 7.3% (38 of 520
patients). Increased risk of mortality and sequelae was associ-
ated with high age, atypical symptoms and severely impaired
mental status (Table 1). Five (4.5%) of the 110 cases in the ID
group died, vs. 33 (8.0%) of the 410 patients in the non-ID
group (p 0.21; Table 2). Information about sequelae at follow-
up 2 to 6 months after discharge was reported in 379
(78.6%) of the 482 surviving patients, and in similar frequencies
in the ID group (82 of 110, 78.1%) as in the non-ID group (297
of 377, 78.8%). The risk of sequelae was 24.4% in the ID group
vs. 43.6% in the non-ID group (adjusted OR: 0.55; 95% CI: 0.31
to 1.00; p 0.05).
In stratiﬁed analyses restricted to patients who received
appropriate antibiotics and corticosteroid treatment <1 hour
from admission, similar outcomes were observed in the ID
group as the non-ID group (1 of 41, 2.4% vs. 2 of 84, 2.4% for
mortality and 9 of 31, 29.0% vs. 25 of 65, 38.5% for sequelae).
Sequences of LP, cerebral CT and treatment
Antibiotics and corticosteroids were administered <1 hour
from admission in similar frequencies if started before LP (62 of
210, 29.5%) as if LP preceded treatment (49 of 191, 25.7%). LP
was performed without prior neuroimaging signiﬁcantly more
often in the ID group; in 61 of 107 (57.0%) patients compared
with 136 of 386 (35.3%) in the non-ID group (adjusted OR 2.14;
95% CI: 1.30 to 3.53; p 0.003) (Table 3). Treatment was started
without a prior CT scan signiﬁcantly more often in the ID group
(76 of 88, 86.4%) compared with the non-ID group (190 of 332,
57.2%; p < 0.001) with an OR of 4.83 (95% CI: 2.45 to 9.52;
p < 0.001) adjusted for confounders. The sequence of brain CTand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 560–566
TABLE 2. Comparison between the patients initially managed by ID and non-ID physicians for the main outcomes: antibiotic
treatment <1 hour and <2 hours, treatment with antibiotics and corticosteroids <1 hour from admission, mortality during
hospital stay, and neurological deﬁcit and/or hearing deﬁcit (sequelae) at follow-up after 2 to 6 months
ID physician
n [ 110 (%)
Non-ID physician
n [ 410 (%)
Univariate odds
ratio* (95% CI)
Adjusted odds
ratio*,† (95% CI)
Antibiotics <1 h from admission: n/n available data‡ 44/96 (45.8) 97/323 (30.0) 1.97 (1.24–3.14) 2.25 (1.31–3.85)
Antibiotics <2 h from admission: n/n available data‡ 72/96 (75.0) 162/323 (50.2) 2.98 (1.79–4.97) 3.74 (2.07–6.74)
Antibiotics and corticosteroids <1 h from admission: n/n available data‡ 41/101 (40.6) 84/351 (23.9) 2.17 (1.36–3.46) 2.41 (1.40–4.14)
Mortality during hospital stay: n/n available data 5/110 (4.5) 33/410 (8.0) 0.54 (0.21–1.43) 0.91 (0.31–2.69)
Sequelae at follow-up after 2–6 months: n/n available data 20/82 (24.4) 129/296 (43.6) 0.42 (0.24–0.73) 0.55 (0.31–1.00)
Favourable outcome§: n/n available data 62/87 (71.3) 167/329 (50.8) 2.41 (1.44–4.02) 1.72 (0.98–3.01)
ID, infectious disease; CI, conﬁdence interval.
*Non-ID used as reference.
†Odds ratio adjusted for sex, age, immunocompromised state, clinical presentation with typical acute bacterial meningitis symptoms, mental status on admission, concomitant
respiratory tract infection and aetiology. Logistic regression analyses were performed for CIs.
‡Data for door-to-antibiotic time was available in altogether 419 patients. In a further 33 cases, concomitant corticosteroids were not given. Thus, data for appropriate treatment <1
hour was available in altogether 452 patients.
§Survivors without sequelae at follow-up after 2 to 6 months.
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cantly more often in the non-ID group (77 of 298 (25.8%) vs. 5
of 77 (6.5%).DiscussionABM is a fulminant disease with a considerable risk of death or
persisting neurological deﬁcits [1,5,6]. Less than half of the
patients present with the typical symptoms of fever, headache,
neck stiffness and impaired consciousness [5]. Because it is a
rare disease, the clinical experience of ABM cases is very limited
for most physicians. Immediate appropriate treatment with
antibiotics and corticosteroids is pivotal for a favourable
outcome but adherence to current guidelines is limited, and
only a minority of ABM patients is started on antibiotics <1
hour from admission as recommended [1,3,7,8,10,11,26,27].
Thus, ABM is a real challenge, demanding good clinical knowl-
edge of the admitting physician in the emergency room.
This is, to our knowledge, the ﬁrst study evaluating initial
management in ABM by an ID physician vs. a non-ID physician.
As shown previously, early treatment was associated withTABLE 3. Diagnostic treatment management on admission by ID p
ID physician, n[ 110 (%),
n/n available data
LP performed 100/109 (91.7)
CT brain performed 83/110 (75.5)
LP followed by antibiotics 51/103 (49.5)
LP without prior CT brain 61/107 (57.0)
Antibiotics without prior CT brain 76/88 (86.4)
CT brain followed by LP followed by antibiotics 5/77 (6.5)
LP followed by antibiotics but without prior CT brain 46/103 (44.7)
ID, infectious disease; CI, conﬁdence interval; LP, lumbar puncture; CT, computerized tomo
*Non-ID used as reference.
†Odds ratio adjusted for sex, age, immunocompromised state, clinical presentation with typic
and aetiology. Logistic regression analyses were performed for CIs.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectyoung age, absence of underlying conditions, typical symptoms,
severely impaired mental status and meningococcal aetiology,
and unfavourable outcome was associated with older age,
atypical symptoms and severely impaired mental status
[1–3,7–9]. Appropriate treatment with antibiotics and corti-
costeroids <1 hour from admission, in line with current
guidelines, was achieved signiﬁcantly more often (41%) by ID
physicians compared with non-ID physicians (24%) even after
adjustment for potential confounders. The door-to-antibiotic
time was signiﬁcantly shorter, and more patients were admin-
istered corticosteroids together with the ﬁrst doses of antibi-
otics in the ID group.
Faster appropriate treatment has been associated with less
mortality and sequelae [1–3,9,10,12,13]. In the present study
the shorter door-to-antibiotic time in ID physician-treated
patients was associated with a decreased risk of mortality
(4.5% vs. 8.0%) and sequelae (24% vs. 44%), but these differ-
ences did not reach statistical signiﬁcances (p 0.21 and p 0.05
adjusted for confounders). Because similar outcomes were
observed in the two groups if antibiotics and corticosteroids
were started <1 hour after admission, the decisive differences
between the two groups causing diverse clinical outcomes werehysicians compared with non-ID physicians
Non-ID physician, n[ 410 (%),
n/n available data
Univariate odds
ratio* (95% CI)
Adjusted odds
ratio*,† (95% CI)
379/402 (94.3) 0.67 (0.30–1.50) 0.57 (0.24–1.37)
323/395 (81.8) 0.69 (0.41–1.13) 0.93 (0.53–1.64)
162/381 (42.5) 1.33 (0.86–2.05) 1.06 (0.66–1.69)
136/385 (35.3) 2.43 (1.57–3.76) 2.14 (1.30–3.53)
190/332 (57.2) 4.73 (2.48–9.04) 4.83 (2.45–9.52)
77/298 (25.8) 0.20 (0.08–0.51) 0.20 (0.08–0.52)
75/364 (20.6) 3.11 (1.96–4.95) 2.89 (1.68–4.98)
graphy.
al ABM symptoms, mental status on admission, concomitant respiratory tract infection
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 560–566
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priate treatment. The remarkably low mortality of 2.4% in these
appropriately treated patients supports the use of corticoste-
roids, an issue that remains controversial [15].
Earlier studies indicate that neuroimaging before antibiotic
treatment is common and associated with delayed treatment
and unfavourable outcome [3,7,8,10,17]. CSF analysis is the
mainstay in the diagnosis of ABM and in clinical practice LP is
often required to initiate appropriate treatment. International
guidelines recommend cerebral CT before LP in many cases
[13,14], but due to lack of evidence, impaired mental status has
been retracted as a contraindication for immediate LP in the
Swedish guidelines for ABM in adults [7,8,28]. The present
study indicates that ID physicians adhere better to the current
Swedish guidelines, as LP was performed signiﬁcantly more
often without a prior CT scan in the ID group compared with
the non-ID group. Furthermore, ID physicians started antibi-
otics without prior neuroimaging more often than non-ID
physicians, which is important to achieve the goal of early
treatment in ABM. Finally, the sequence of cerebral CT fol-
lowed by LP followed by antibiotics was performed more often
by non-ID physicians (33%) vs. ID physicians (12%), and this
sequence was associated with an increased mortality (12.2%;
data not shown) as previously shown [3].
The large sample size enabled us to consider several possible
confounders by multivariate analyses, which strengthen the
results of the study, and the high coverage (85%) indicates that
the results are generalizable. Physicians specialized in internal or
emergency medicine were the most common medical special-
ities and performed similarly regarding door-to-antibiotic time,
diagnostic treatment sequences and clinical outcomes (data not
shown). Expert knowledge about ABM may differ between
medical specialities in different countries. Our data indicate that
it is important that patients with ABM are initially managed by
physicians with high vigilance for ABM, performing appropriate
diagnostic procedures and initiating prompt treatment, and that
non-ID physicians at emergency departments need training in
the management of ABM.
The main limitations of the present study are the retrospective
design with lack of randomization and control of original data.
However, a randomized clinical trial would, for ethical and logistic
reasons, be problematic. In a few patients an explicit diagnosis was
not conﬁrmed by laboratory analyses, but by including all patients
with a clinical diagnosis we believe that the generalizability became
higher. Patients in the non-ID group were older and more
mentally affected, which is a weakness of the study, but adjustment
for these and other important variables (underlying condition,
typical ABM symptoms, respiratory tract infection and aetiology)
[1–3,5–9] did not noticeably affect the results. However,
adjustment for other important but less common measures ofClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologydisease severity, such as septic shock, seizures and low CSF
leukocyte count [5], would have been desirable.ConclusionsAlthough a relatively low overall mortality of 7.3% was
observed, our report underlines the risk of morbidity and the
difﬁculties and challenges to achieving appropriate timely
management of adult community-acquired ABM. Better
adherence to current guidelines for the diagnostic treatment
recommendations associated with earlier treatment and
favourable clinical outcome were observed among ID physi-
cians compared with non-ID physicians. Thus, expert knowl-
edge is important in the early management of adult ABM.Transparency declarationThis work was supported by research and development funds
of the Karolinska and Uppsala University Hospitals. The authors
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